-
Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety
Monday, October 4, 2021 - 6:49am | 317Read More...Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related macular degeneration (wet AMD). Data were shared at the Retina Society's Annual Scientific Meeting. The 2 x 10^11 vg/eye dose...
-
Why Are Viridian Therapeutics Shares Moving Higher On Tuesday?
Tuesday, September 21, 2021 - 8:24am | 262Read More...Viridian Therapeutics Inc (NASDAQ: VRDN) has priced an underwritten public offering with approximately $85.0 million gross proceeds. Viridian will offer 6.18 million shares at $11.00 per share, and 23,126 shares of series B preferred stock at a public offering price of $733.37 per...
-
Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
Tuesday, September 21, 2021 - 7:07am | 251Read More...Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Deal terms were not disclosed. Related: Why Did Deutsche Bank Downgrade This Big...
-
Tarsus Pharma Partners With LianBio For TP-03 In Greater China For Eye Diseases
Tuesday, March 30, 2021 - 7:14am | 199Read More...Tarsus Pharmaceuticals Inc (NASDAQ: TARS) and LianBio have announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational...
-
Here's Why Ophthotech Is Trading Down On Regeneron's News
Friday, September 30, 2016 - 11:45am | 474Read More...Ophthotech Corp (NASDAQ: OPHT), a biopharmaceutical company that develops therapeutics for the treatment of eye diseases, saw its shares fall more than 13 percent Friday. The decline is attributed to an announcement by Regeneron Pharmaceuticals Inc (NASDAQ: REGN), a larger biopharmaceutical...
-
Aerie Pharmaceuticals Announces Initiation Of Second Phase 3 Trial For Roclatan
Monday, March 28, 2016 - 9:05am | 275Read More...Aerie Pharmaceuticals Inc (NASDAQ: AERI), a clinical-stage pharmaceutical company that focuses on the treatment of glaucoma and other diseases of the eye, announced on Monday that it has successfully began dosing the first patients enrolled in Mercury 2, the company's second Phase 3 registration...
-
Eyegate Pharmaceuticals Spikes 12%; Co. Eligible To Receive Milestone Payment From Valeant
Wednesday, March 2, 2016 - 12:47pm | 192Read More...Shares of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG), a nano-cap clinical-stage specialty pharmaceutical company that focuses on treatment for diseases of the eye, gained more than 12 percent on Wednesday. Eyegate announced that it has received an additional development milestone from Valeant...
